Immune Medicine Platform Applications for COVID-19
Adaptive is proud to partner with industry leaders to respond to this global health pandemic
At Adaptive, we are leveraging the immune system’s natural ability to detect and treat disease to develop clinical products. Understanding the immune response to COVID-19 may lead to solutions to accelerate progress against the disease.
We are pursuing two separate but synergistic applications of our immune medicine platform to combat COVID-19:
– In March 2020, we extended our existing partnership with Microsoft to decode the immune system’s response to COVID-19 and potentially develop a more sensitive diagnostic that can detect disease earlier or indicate who has been previously infected.
– In April 2020, we began to leverage our platform’s drug discovery capabilities to screen for antibody therapies for COVID-19.
Decoding the Immune Response to COVID-19
A group of industry leaders has come together to accelerate this critical effort.
To address the COVID-19 pandemic, Adaptive and Microsoft have extended our existing partnership to map population-wide adaptive immune responses to diseases at scale to identify how the immune system responds to COVID-19. We will make our findings freely available to all researchers around the world. This program is called ImmuneCODE.
By decoding the immune system’s response to COVID-19, we may help advance solutions to diagnose, treat, and prevent the disease, complementing existing efforts underway to understand the virus itself.
We will generate immune response data and identify an immune response signature to COVID-19 in the following ways:
– Internal research: Utilizing our MIRA technology, we will identify coronavirus-specific (immunogenic) antigens and T-cell receptors that react to those antigens.
– Our ImmuneRACE Study: Through our sponsored study, we will collect de-identified blood samples and nasal or throat swabs from individuals who are currently fighting, have recently recovered from, or have been exposed to the COVID-19 virus.
– Partnerships with participating institutions: We are partnering with institutions around the world to secure patient samples.
A key goal of the ImmuneCODE Program is to enable scientific researchers around the world to further their own research to enable the more effective diagnosis, treatment, and prevention of COVID-19 through free, open sharing of population-level immune response data. Read more about the data we are sharing here.
Reach out to discuss contributing samples
IMMUNOSEQ T-MAP COVID
Comprehensive view of SARS-CoV-2 specific antigen and TCR sequence level data
T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, often before symptoms appear. Adaptive’s unique MIRATM technology and immunoSEQ® Technology has enabled us to create the comprehensive view of the T-cell response to SARS-CoV-2 infection. This data has been made public as part of ImmuneCODE in order to help propel drug, vaccine, and clinical trial research. We are launching immunoSEQ T-MAP COVID with the tools to study and analyze the COVID-19 T-cell immune response map.
– SARS-CoV-2-specific Antigen-TCR sequence-level data
Quantitative sequence level data for TCR repertoires for SARS-CoV-2-specific antigens
– Monitor immunologic response to SARS-CoV-2 infection or vaccine
Track COVID-19 specific TCR sequences longitudinally
– Dive into Patient, Population, or Cohort-level data
Determine TCR clones shared between cohorts & those that are Public vs Private clones
Therapeutic Antibodies Against COVID-19 Virus
In April 2020, we began to leverage our platform’s drug discovery capabilities to discover fully human neutralizing antibodies to potentially speed the recovery from or prevent COVID-19 under a memorandum of understanding with Amgen.
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
Adaptive will extend its high-throughput immune medicine platform to rapidly screen the massive genetic diversity of the B-cell repertoire. This enables us to identify tens of thousands of naturally occurring BCRs from survivors of COVID-19 to characterize the best antibodies that neutralize SARS-CoV-2 and potentially other related coronaviruses. We recently entered into an agreement with Amgen, whereby Amgen has the option to review Adaptive’s neutralizing antibody candidates and take them forward into development and commercialization.